IL6 and COVID-19: The anti-cytokine and anti-viral activities of baricitinib are primarily responsible for the clinical and radiological recovery, a rapid reduction in the viral load, inflammatory markers, and IL-6 levels in COVID-19 (Stebbing et al., 2020).